residual cv risk in treated h hypertension and total cv risk in friedreich ataxia cardiovascular involvement diagnosis and management of dyslipidemia in special popula introducing nephro-cardiology anti-anginal drugs impact of non-adherence to antihypertensive medica the five dimensions of non-adherence benefit-risk profile of sglt2 inhibitors ( glifloz several sglt2 inhibitors have completed phase 3 cl similarities and differences between hfa and inter noninvasive multimodality imaging in the diagnosi 74:905–27 ) jacc scientific expert panel ( j am coll cardiol 2 radiation associated cardiac disease cardiac evaluation algorithm for liver transplant connections between hepatic and cardiovascular dis shifting the paradigm in diabetes care treating di anti-diabetics for cardiac patients the proper sel board scheme for the therapy of patients with acut peripartum cardiomyopathy t3 has both genomic and nongenomic effects on the thyroid hormones and cardiovascular function and d which as their modes of action suggest oppose each the cornerstones of therapy are beta-blockers and association of cardiovascular disease with respira the clinical challenge of concomitant aortic and m challenges in multivalvular disease should you use doacs for cancer-associated vte?.cr from hypertension to heart failure role of the renin–angiotensin–aldosterone system i cardio-renal protection through renin–angiotensin fourth universal definition of myocardial infarcti psychopharmacology and cardiovascular disease obesity and cardiovascular disease iron therapy for the treatment of iron deficiency vitamin d and cardiovascular disease where do we s what is diuretic resistance?how to tackle congesti myocardial infarction with non-obstructive corona minoca new guidelines for managing patients with high blo perioperative management of hypertension blood pressure targets  2017.still struggling f esc 2016 risk categories & ldl goal recommendations for treatment targets for ldl-c pros and cons of anticoagulants in cirrhotic patie arrhythmia-induced cardiomyopathy precautions to minimize exposure to patient and dr ticagrelor versus clopidogrel acute coronary syndrome.dual antiplatelet therapy. cardiac amyloidosis acute coronary syndrome dual antiplatelet therapy invidualised antiplatelet therapy percutaneous coronary intervention ppi dapt and oral anticoagulants hypertension and coronary artery disease new guidelines 2015 jnc8 controversy blood pressure targets hypertension 2014-2015 guidelines antianginal drugs stable coronary artery esc guidelines 2013 2014 european society of cardiology guidelines hypertrophic cardiomyopathy leaflet motion cinefluoroscopy prosthetic jnc 8 -2014 esh/esc 2013 microvascular angina
Tout plus